Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: An observational cohort study

The Lancet HIV

Volumn 2, Issue 10, 2015, Pages e445-e450

  Ahamad, K ^a,b,c   Hayashi, K ^a,c   Nguyen, P ^a,c   Dobrer, S ^a,c   Kerr, T ^a,b,c   Montaner, J S ^a,b,c   Wood, E ^a,b,c   Schutz C G ^b,c  

^a ST PAUL S HOSPITAL   (Canada)

^b Department of Family Practice ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; NARCOTIC AGENT;

ARTICLE; CANADA; COMMUNITY CARE; DISEASE TRANSMISSION; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAINTENANCE THERAPY; MORBIDITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; QUESTIONNAIRE; STATISTICAL ANALYSIS; STRUCTURED INTERVIEW; TREATMENT OUTCOME; ADULT; BRITISH COLUMBIA; COHORT ANALYSIS; COMPLICATION; DRUG THERAPY; FEMALE; HIV INFECTIONS; HUMAN; INCIDENCE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; SUBSTANCE ABUSE;

ADULT; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MAINTENANCE CHEMOTHERAPY; MALE; METHADONE; MIDDLE AGED; NARCOTICS; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84947023998     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(15)00129-0     Document Type: Article

References (35)

1. Joint UN Programme on HIV/AIDS. Report on the global AIDS epidemic. Geneva, 2013. http://www.unaids.org/sites/default/fi les/ media_asset/UNAIDS_Global_Report_2013_en_1.pdf (accessed July 31, 2015).
2. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-45.
3. Joint UN Programme on HIV/AIDS. UNAIDS Strategy 2011-2015. 2011. http://www.unaids.org/en/aboutunaids/unaidsstrategygoals by2015 (accessed Nov 3, 2014).
4. UN Offi ce on Drugs and Crime. World Drug Report 2014. http:// www.unaids.org/sites/default/fi les/media_asset/UNAIDS_Global_ Report_2013_en_1.pdf (accessed July 31, 2015).
5. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012; 345: e5945.
6. Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006; 101: 252-66.
7. Niccolai LM, Toussova OV, Verevochkin SV, Barbour R, Heimer R, Kozlov AP. High HIV prevalence, suboptimal HIV testing, and low knowledge of HIV-positive serostatus among injection drug users in St. Petersburg, Russia. AIDS Behav 2010; 14: 932-41.
8. Rhodes T, Lowndes C, Judd A, et al. Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS 2002; 16: F25-F31.
9. Elovich R, Drucker E. On drug treatment and social control: Russian narcology's great leap backwards. Harm Reduct J 2008; 5: 23.
10. Parfi tt T. Vladimir Mendelevich: fi ghting for drug substitution treatment. Lancet 2006; 368: 279.
11. Peterson JA, Schwartz RP, Mitchell SG, et al. Why don't out-oftreatment individuals enter methadone treatment programmes? Int J Drug Policy 2010; 21: 36-42.
12. Schwartz RP, Jaff e JH, Highfi eld DA, Callaman JM, O'Grady KE. A randomized controlled trial of interim methadone maintenance: 10-month follow-up. Drug Alcohol Depend 2007; 86: 30-36.
13. Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy 2000; 21: 187-210.
14. Luce J, Strike C. A cross-Canada scan of methadone maintenance treatment policy developments. A report prepared for the Canadian Executive Council on Addictions 2011. http://www.ceca-cect.ca/pdf/ CECA%20MMT%20Policy%20Scan%20April%202011.pdf (accessed July 31, 2015).
15. Anderson JF, Warren LD. Client retention in the British Columbia methadone program, 1996-1999. Can J Public Health 2004; 95: 104-49.
16. Metzger DS, Woody GE, McLellan AT, et al. Human immunodefi ciency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defi c Syndr 1993; 6: 1049-56.
17. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994; 8: 223-32.
18. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113 (suppl 1): 107.
19. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997; 11: F59-65.
20. College of Physicians and Surgeons of British Columbia. Methadone maintenance program: Clinical practice guideline. 2014. http://www.cpsbc.ca/fi les/pdf/MMP-Clinical-Practice-Guideline.pdf (accessed June 4, 2015).
21. Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004; 94: 1218-23.
22. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997; 11: F59-65.
23. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001; 357: 1397-401.
24. Maldonado G, Greenland S. Simulation study of confounderselection strategies. Am J Epidemiol 1993; 138: 923-36.
25. Bell J, Hall W, Byth K. Changes in criminal activity after entering methadone maintenance. Br J Addict 1992; 87: 251-58.
26. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
27. Maremmani I, Pani PP, Pacini M, Perugi G. Substance use and quality of life over 12 months among buprenorphine maintenancetreated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat 2007; 33: 91-8.
28. Carrieri PM, Michel L, Lions C, et al. Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville). PLoS One 2014; 9: e112328.
29. Wittchen H-U, Apelt SM, Soyka M, et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008; 95: 245-57.
30. Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA 2000; 283: 1343-48.
31. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001; 286: 1724-31.
32. Keen J, Oliver P, Rowse G, Mathers N. Does methadone maintenance treatment based on the new national guidelines work in a primary care setting? Br J Gen Pract 2003; 53: 461-67.
33. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-68.
34. Wood E, Lloyd-Smith E, Li K, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med 2007; 120: 172-79.
35. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41: 777-813.